Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?
(HealthDay News) — Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online Feb. 12 in JAMA Psychiatry.
New Delhi: Noting that post-marketing safety data in Indian patients is not presented, the Subject Expert Committee (SEC) ...
Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.
Vietnam Investment Review on MSN2d
Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U S FDA Clearance of IND Application for ASC47 in Combination with SemaglutideASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and 40 days, respectively, in Phase Ib single ...
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
The 40-week SUSTAIN 7 trial investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin.
Ascletis Announces Positive ASC47 Phase Ib Pharmacokinetic & Weight Loss Data From Australia Studies
Each cohort consists of a single low dose of ASC47 and four doses of semaglutide (0.5 mg, once weekly). Cohorts 1-3 have ASC47 low doses of 10 mg, 30 mg, and 60 mg, respectively. Each cohort has ...
Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...
Weight loss drugs like Ozempic, while transformative in combating obesity, have been linked to irreversible vision impairment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback